For T cell checkpoint targets such as VISTA and CTLA-4, activity both in the immune synapse and in activated lymphoid microenvironments may represent a significant secondary locus of action that contributes to their anti-tumor activity. The gene discussed is VSIR; the disease is neoplasm.